

Sanofi  
Form 6-K  
June 12, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June 2012

Commission File Number: 001-31368

**SANOFI**

(Translation of registrant's name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

## Edgar Filing: Sanofi - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In June 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 to 99.5 which are incorporated herein by reference.

**Exhibit List**

Exhibit	
No.	Description
Exhibit 99.1	Press release dated June 9, 2012: Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes
Exhibit 99.2	Press release dated June 9, 2012: Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Reduced HbA <sub>1c</sub> and Post-Prandial Glucose
Exhibit 99.3	Press release dated June 11, 2012: Sanofi Announces Results of ORIGIN, the World's Longest and Largest Randomized Clinical Trial in Pre- and Early Diabetes
Exhibit 99.4	Press release dated June 11, 2012: New Epidemiological Data Provide Additional Safety Evidence for Lantus®
Exhibit 99.5	Press release dated June 12, 2012: Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA (alemtuzumab) for Multiple Sclerosis

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 12, 2012

SANOFI

By /S/ John Felitti  
Name: John Felitti  
Title: Associate Vice President, Corporate Law, Financial &  
Securities Law

**Exhibit Index**

Exhibit	
No.	Description
Exhibit 99.1	Press release dated June 9, 2012: Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes
Exhibit 99.2	Press release dated June 9, 2012: Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Reduced HbA <sub>1c</sub> and Post-Prandial Glucose
Exhibit 99.3	Press release dated June 11, 2012: Sanofi Announces Results of ORIGIN, the World's Longest and Largest Randomized Clinical Trial in Pre- and Early Diabetes
Exhibit 99.4	Press release dated June 11, 2012: New Epidemiological Data Provide Additional Safety Evidence for Lantus®
Exhibit 99.5	Press release dated June 12, 2012: Genzyme Submits Applications to FDA and EMA for Approval of LEMTRADA (alemtuzumab) for Multiple Sclerosis